Statement of Deficiencies	**(X1) Provider/Supplier/CLIA Identification Number**	**(X3) Date Survey Completed**
	13D2014037	04/19/2018
Name of Provider or Supplier	**Street Address, City, State**	
The Pain Center	633 N 4th St, Boise, ID	

For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D5439	CALIBRATION AND CALIBRATION VERIFICATION CFR(s): 493.1255(b) Unless otherwise specified in this subpart, for each applicable test system the laboratory must do the following: Perform and document calibration verification procedure - (b)(1) Following the manufacturer's calibration verification instructions; (b)(2) Using the criteria verified or established by the laboratory under 493.1253(b)(3) -- (b)(2)(i) Including the number, type, and concentration of the materials, as well as acceptable limits for calibration verification; and (b)(2)(ii) Including at least a minimal (or zero) value, a mid-point value, and a maximum value near the upper limit of the range to verify the laboratory's reportable range of test results for the test system; and (b)(3) At least once every 6 months and whenever any of the following occur: (b)(3)(i) A complete change of reagents for a procedure is introduced, unless the laboratory can demonstrate that changing reagent lot numbers does not affect the range used to report patient test results, and control values are not adversely affected by reagent lot number changes. (b)(3)(ii) There is major preventive maintenance or replacement of critical parts that may influence test performance. (b)(3)(iii) Control materials reflect an unusual trend or shift, or are outside of the laboratory's acceptable limits, and other means of assessing and correcting unacceptable control values fail to identify and correct the problem. (b)(3)(iv) The laboratory's established schedule for verifying the reportable range for patient test results requires more frequent calibration verification. This STANDARD is not met as evidenced by: Based on a record review and an interview with the laboratory supervisor, the laboratory failed to perform and document calibration verification procedures at least once every 6 months on the Thermo Fisher Indiko Plus chemistry analyzer used to test drugs of abuse since the last survey on September 14, 2016. Findings: 1. A record review of calibration reports for amphetamine, barbiturate, cannabinoid, cocaine, ethyl alcohol, methadone, opiate, oxycodone, buprenorphine, and benzodiazepine

	revealed the laboratory failed to perform calibration verification on all analytes, except buprenorphine, since the last survey. 2. An interview on April 19, 2018, at 10: 30 AM, with the laboratory supervisor, confirmed the laboratory failed to perform calibration verifications on the drugs of abuse analytes except buprenorphine.